To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
Prospective, Post-authorisation, Multi-centre, Non-interventional Study to Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice
Ferring Pharmaceuticals
2,500 participants
Aug 5, 2025
OBSERVATIONAL
Conditions
Summary
This is a multi-centre prospective non-interventional trial to assess the pattern of use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice. There will be approximately 2500 patients initiated with REKOVELLE® treatment and enrolled in 30-50 sites in China. The total duration of the study will be approximately 35 months.
Eligibility
Inclusion Criteria4
- Women who meet all the following criteria are eligible for participation:
- At least 20 years of age (including the 20th birthday) when signing informed consent
- Prescribed REKOVELLE for the first time in controlled ovarian stimulation for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles
- Willing and able to provide written informed consent
Exclusion Criteria5
- Women who meet any of the following criteria are not eligible for participation:
- Previously undergone more than 1 controlled ovarian stimulation cycles for IVF or ICSI
- Currently participating in an interventional clinical study for which treatment with medication is mandated
- Currently undergoing ovarian stimulation for fertility preservation or oocytes donation
- Contraindications for the use of REKOVELLE
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(28)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07029451